Trademark "BSIM Therapeutics" registered in the USA

In parallel with its main goal of developing innovative and patient-centered therapeutics for transthyretin-mediated amyloidoses (ATTR), BSIM also strives for worldwide recognition of its identity. After the initial registration in Europe, followed by China and Japan, BSIM Therapeutics now sees its trademark registered in the USA (No. 6398721). We reaffirm our commitment to see our name associated with the best therapeutic options for the treatment of ATTR.